Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence [Breast Cancer]
Conclusion
Both persistence and compliance are associated with DFS. Toxicity management and, for sequential treatments, patient and physician awareness, may improve adherence. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Chirgwin, Giobbie-Hurder, Coates, Price, Ejlertsen, Debled, Gelber, Goldhirsch, Smith, Rabaglio, Forbes, Neven, Lang, Colleoni, Thurlimann Tags: Hormonal Therapy Breast Cancer Source Type: research
KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma [Rapid Communication]
Conclusion
We conclude that KIR3LD1 and HLA-B allele combinations can have a prognostic impact on patient survival after treatment with anti-GD2 mAb that relies on NK-ADCC. The survival advantage seen in noninteracting combinations supports the therapeutic disinhibition of individuals with strongly interacting KIR and ligand pairs. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Forlenza, Boudreau, Zheng, Le Luduec, Chamberlain, Heller, Cheung, Hsu Tags: Neuroblastoma, Rapid Communications, Rapid Communications, Immunology/Immunobiology Source Type: research
Sticking to It: Improving Outcomes by Increasing Adherence [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Hershman Tags: Hormonal Therapy EDITORIALS Source Type: research
The Beginning of the End of Package Deal Therapy for Patients With High-Risk Neuroblastoma? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Authors: Barrett, Bagatell Tags: Neuroblastoma EDITORIALS Source Type: research
Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - July 12, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research
Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Tags: ERRATUM Source Type: research
Reply to T. Magnes et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Deenen, Cats, Severens, Beijnen, Schellens Tags: CORRESPONDENCE Source Type: research
Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Magnes, Melchardt, Weiss, Hufnagl, Greil, Egle Tags: CORRESPONDENCE Source Type: research
Reply to T.A. Yap et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Sweis, Ratain Tags: CORRESPONDENCE Source Type: research
Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Yap, Banerji, de Bono, Workman Tags: CORRESPONDENCE Source Type: research
Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Beumer, Tawbi, Ivy Tags: CORRESPONDENCE Source Type: research
Harmonization of Renal Function Assessment Is Needed Throughout the Whole Process of Anticancer Drug Development [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Porta, Cosmai, Gallieni, Perazella Tags: CORRESPONDENCE Source Type: research
Obvious Pitfall in the Estimation of Renal Dysfunction [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Shimokata, Yasuda, Ando Tags: CORRESPONDENCE Source Type: research
Renal Dysfunction Has Statistically and Clinically Significant Deleterious Effects on Anticancer Drug Safety [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Launay-Vacher Tags: CORRESPONDENCE Source Type: research
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline [ASCO SPECIAL ARTICLE]
Purpose
A Cancer Care Ontario (CCO) guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer including adjuvant targeted therapy for human epidermal growth factor receptor 2 (HER2)–positive breast cancers was identified for adaptation.
Methods
The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for adapting clinical practice guidelines developed by other organizations. The CCO guideline was reviewed for developmental rigor and content applicability.
Results
On the basis of the content review of the CCO guideline, the ASCO Panel agreed that, in gene...
Source: Journal of Clinical Oncology - June 30, 2016 Category: Cancer & Oncology Authors: Denduluri, Somerfield, Eisen, Holloway, Hurria, King, Lyman, Partridge, Telli, Trudeau, Wolff Tags: Epidemiology, Chemotherapy, Combined Modality, Hormonal Therapy, ASCO Guidelines, Non-ASCO Guidelines ASCO SPECIAL ARTICLE Source Type: research
